Experience with bevacizumab in the management of epithelial ovarian cancer.
about
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.Targeted therapies in epithelial ovarian cancer.Targeted therapy in ovarian cancer.Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy.Whole genome expression profiling of blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14.Proteomics and ovarian cancer: integrating proteomics information into clinical careOvercoming platinum resistance in ovarian carcinoma.Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.Bevacizumab in the treatment of ovarian cancer.Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogsHypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death.Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancerAntiangiogenic drugs in ovarian cancer.Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer.Bevacizumab toxicities and their management in ovarian cancer.The rationale for mTOR inhibition in epithelial ovarian cancer.Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.Targeted agents in ovarian cancer.Emerging therapeutics for primary peritoneal cancer.Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.Reducing excessive toxicity in ovarian cancer treatment: a personalized approach.Bevacizumab and its use in epithelial ovarian cancer.Sudden visual loss in the untreated eye of a patient with neovascular glaucoma following an intravitreal bevacizumab injection: A case report.Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer.A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
P2860
Q30429122-C594D68C-BC43-414A-ABCD-BF96028B9CD0Q33606699-63A4AE2A-5C9C-462D-87FC-DFACAA1626F8Q33622179-22973D3D-84B8-44BB-8539-ACFFEFA9D5F0Q33771212-CF04A395-1F62-4725-8E4F-5B53AA1FA4E5Q33780751-26966B66-17DC-49EB-B74F-F19AC14ABAC4Q34048965-3A30106F-925B-4796-A897-968C56436E15Q34100848-9AF06FD8-44DF-4E58-AD80-E0BA49513853Q34126627-827BB793-999F-4359-8222-CF44F452D470Q34233273-8FB249BB-B0B0-4A62-9627-431F6B62B57DQ34557233-B1E4C15C-8E34-4FBD-91DB-7ACCDEB91631Q34605261-9B1443C0-FFFF-48DD-ACB1-1E32F62B8566Q35216301-12595910-C950-4C1E-BA8F-BC5EAE40E80CQ35835574-0A59CC51-5591-40FA-A08F-A59A4559DAB9Q36880907-47415B78-B653-4B4C-B87D-0FD12EBC86F3Q36891578-64AF427D-9D6A-45A6-A8E3-7EE2F97CC490Q36910794-35492E44-BECB-474D-B1F1-6DEE5EBA63F5Q37022524-45E97C38-821A-4F92-B4FA-A5F6E7932D26Q37080913-23915539-DF22-4CE1-A50D-7C744F866550Q37123500-31EF29D0-EE93-478A-82A6-A574426B24CEQ37140621-9458DF15-FCE8-47C9-9935-9BEC8CA89D6DQ37141960-DA49961E-9A3E-4C92-9697-0D412C5AF8B9Q37415131-E2D9FB2F-A3A8-44F9-8CA8-699DC4618E75Q37627253-C365259A-BD35-4565-A321-44D0E77BF027Q37665014-B78667A0-FEBB-4523-9459-7C7F930B599EQ37795802-E54A807B-C9AC-48FD-A873-26888053F684Q37847177-AEFBB754-D4F9-4796-82AC-900458E26033Q38003707-DA5EE0B2-E1C6-4075-9E19-234CC91F4EDEQ38111265-6ADF063A-3337-4594-84A5-4C2B38209119Q38849896-CF7A7F88-E618-403B-A1A6-5F6A7785A67BQ39739012-EA3D7AB9-ED71-4E77-A3B4-F1F6082A4F4EQ39782817-DD104849-86A8-48A9-A9DF-2C2DB94E304DQ41837052-25F92958-3DAC-4BC8-9A3D-2C1D029166E5Q45423656-3FDA61B3-7918-4CF2-9DC6-76466FFA731CQ47562932-386C2360-828E-42B9-BCDB-1FCFF22CFDA8Q48746366-0EBE9C56-7A5F-4867-97B7-CA48B7B3FE2D
P2860
Experience with bevacizumab in the management of epithelial ovarian cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Experience with bevacizumab in the management of epithelial ovarian cancer.
@en
type
label
Experience with bevacizumab in the management of epithelial ovarian cancer.
@en
prefLabel
Experience with bevacizumab in the management of epithelial ovarian cancer.
@en
P356
P1476
Experience with bevacizumab in the management of epithelial ovarian cancer.
@en
P2093
Robert A Burger
P304
P356
10.1200/JCO.2007.12.1509
P407
P577
2007-07-01T00:00:00Z